NRAS and melanoma: One study assessing ctDNA in patients with high-risk stage II or III resected melanoma with BRAF or NRAS mutations enrolled in the AVAST-M trial found that detectable ctDNA was a significant predictor for decreased disease-free interval and distant metastasis-free interval, even after adjusting for performance status and disease stage [67].